Octagon Capital Advisors LP Takes Position in Capricor Therapeutics, Inc. $CAPR

Key Points

• Octagon Capital Advisors LP acquired a new stake in Capricor Therapeutics, purchasing 450,000 shares valued at approximately $4.27 million, which represents a 0.99% ownership of the company.
• Several other investors, including Citizens Financial Group and Arizona State Retirement System, also increased their stakes during the first quarter, highlighting growing institutional interest in Capricor Therapeutics.
• Research analysts have varied ratings on Capricor, with a consensus price target of $22.56 and eight analysts recommending it as a Buy.

Octagon Capital Advisors LP purchased a new stake in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 450,000 shares of the biotechnology company's stock, valued at approximately $4,270,000. Octagon Capital Advisors LP owned about 0.99% of Capricor Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in CAPR. Citizens Financial Group Inc. RI bought a new position in Capricor Therapeutics during the first quarter valued at approximately $95,000. ProShare Advisors LLC purchased a new stake in Capricor Therapeutics during the 4th quarter valued at $142,000. Voya Investment Management LLC bought a new position in shares of Capricor Therapeutics during the 4th quarter valued at $150,000. Arizona State Retirement System bought a new position in shares of Capricor Therapeutics during the 1st quarter valued at $111,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Capricor Therapeutics by 22.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock worth $178,000 after acquiring an additional 2,361 shares during the period. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Stock Down 1.2%

NASDAQ:CAPR traded down $0.08 during trading hours on Friday, hitting $6.36. 637,936 shares of the stock traded hands, compared to its average volume of 1,163,695. The company has a market cap of $290.78 million, a price-to-earnings ratio of -3.88 and a beta of 0.73. Capricor Therapeutics, Inc. has a 1 year low of $4.20 and a 1 year high of $23.40. The stock has a 50 day moving average price of $7.39 and a 200 day moving average price of $9.78.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. Equities analysts forecast that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on CAPR shares. HC Wainwright reiterated a "buy" rating and set a $24.00 price objective on shares of Capricor Therapeutics in a research report on Thursday. Alliance Global Partners reaffirmed a "buy" rating on shares of Capricor Therapeutics in a research report on Monday, July 14th. Wall Street Zen downgraded shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Jones Trading cut their target price on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday, June 25th. Finally, Roth Capital decreased their price target on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating on the stock in a research report on Monday, July 14th. One analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $22.56.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.